Medtronic Plc Hits New 52-Week Low at USD 75.92

Medtronic Plc, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 75.92 as of May 8, 2026. This decline marks a significant downturn for the stock, which has experienced a 1-year performance drop of 8.41%, contrasting sharply with the S&P 500's impressive gain of 30.63% during the same period. The company's market capitalization stands at USD 113,290 million, categorizing it as a large-cap entity. Medtronic's price-to-earnings (P/E) ratio is currently at 20.00, while its dividend yield is noted at 3.20%. The firm maintains a low debt-to-equity ratio of 0.43, indicating a conservative approach to leverage. Despite the recent price movement, Medtronic has shown resilience in certain financial metrics. The company reported its highest operating cash flow of USD 7,146 million and a return on capital employed (ROCE) of 9.72% in its latest financial results. Additionally, institutional holdings remain robust at 86.93%, reflecting confidence among larger investors. As Medtronic navigates these market conditions, its performance metrics will be closely monitored by stakeholders.